Emerging resistance among bacterial pathogens in the intensive care unit - A European and North American surveillance study (2000-2002)

Annals of Clinical Microbiology and Antimicrobials

Volumn 3, Issue , 2004, Pages

  Jones, Mark E ^a   Draghi, Deborah C ^a   Thornsberry, Clyde ^a   Karlowsky, James A ^a   Sahm, Daniel F ^a   Wenzel, Richard P ^b  

^a Focus Technologies Incorporated   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Antibiotic susceptibility; Intensive care unit

Indexed keywords

AMPICILLIN; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; CEFEPIME; CEFOTAXIME; CEFTRIAXONE; CIPROFLOXACIN; GENTAMICIN; IMIPENEM; OXACILLIN; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TEICOPLANIN; VANCOMYCIN;

ACINETOBACTER; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM ISOLATE; CANADA; DATA ANALYSIS; ENTEROBACTERIACEAE; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; ENZYME SYNTHESIS; ESCHERICHIA COLI; EUROPE; FRANCE; GERMANY; HEALTH SURVEY; HOSPITAL INFECTION; HUMAN; INTENSIVE CARE UNIT; ITALY; MORGANELLA MORGANII; NONHUMAN; NORTH AMERICA; PROTEUS MIRABILIS; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; UNITED STATES;

EID: 9444250412     PISSN: 14760711     EISSN: 14760711     Source Type: Journal    
DOI: 10.1186/1476-0711-3-14     Document Type: Article

References (24)

1. Kollef MH, Fraser VJ: Antibiotic resistance in the Intensive Care Unit. Ann Intern Med 2001, 134:298-314.
2. CDC NNIS system: National nosocomial infections surveillance (NNIS) system report, data summary from January 1992-April issued August 2001. Amer J Infect Contr 2001, 29:400-421. Correction 2001, 30:74.
3. NNIS system report Intensive Care Antimicrobial Resistance Epidemiology (ICARE) Surveillance report, data summary from January 1996 through December 1997. Amer J Infect Contr 1999, 27:279-284.
4. Fridkin SK, Steward CD, Edwards JR, Pryor ER, McGowan JE, Archibald LK, Gaynes RP, Tenover FC: Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: Project ICARE Phase 2. Project Intensive Care Antimicrobial Resistance Epidemiology (ICARE) Hospitals. Clin Infec Dis 1999, 29:245-252.
5. Stephen J, Mutnick A, Jones RN: Assessment of pathogens and resistance (R) patterns among intensive care unit (ICU) in North America (NA): initial report from the SENTRY antimicrobial surveillance program (2001). Presented at the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA 2002. Abstract C2-297
6. Vincent JL, Bihari DJ, Suter PM, Bruining HA, White J, Nicloas-Chaoin MH, Wolff M, Spencer RC, Hemmer M: The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. J Amer Med Assoc 1995, 274:639-644.
7. Hanberger H, Garcia-Rodriguez JA, Gobernado M, the French and Portuguese ICU Study Groups, et al: Antibiotic susceptibility among aerobic Gram-negative bacilli in Intensive Care Units in 5 European countries. JAMA 1999, 281:67-71.
8. Garcia-Rodriguez JA, Jones RN, the MYSTIC study group: Antimicrobial resistance in gram-negative isolates from European intensive care units: data from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) programme. J Chem 2002, 14:25-32.
9. Frank U, Jonas D, Lupke T, Ribeiro-Ayeh B, Schmidt-Eisenlohr E, Ruden H, Daschner FD, National Reference Centre Study Group on Antimicrobial Resistance: Antimicrobial susceptibility among nosocomial pathogens isolated in intensive care units in Germany. Eur J Clin Microbiol Infect Dis 2000, 19:888-891.
10. Fiel S: Guidelines and critical pathways for severe hospital-acquired pneumonia. Chest 2001, 119:412-418S.
11. Laupland KB, Zygun DA, Davies HD, Church DL, Louie TJ, Doig CJ: Incidence and risk factors for acquiring nosocomial urinary tract infection in the critically ill. J Crit Care 2002, 17:50-57.
12. Sahm DF, Draghi DC, Master RN, Thonsberry C, Jones ME, Karlowsky JA, Critchley IA: Pseudomonas aeruginosa antimicrobial resistance update: US resistance trends from 1998 to 2001. Presented at the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA 2002. Abstract C2-305
13. Sahm DF, Marsilio MK, Piazza G: Antimicrobial resistance in key bloodstream bacterial isolates: electronic surveillance with the surveillance network database - USA. Clin Infect Dis 1999, 29:259-263.
14. National Committee for Clinical Laboratory Standards: Methods for dilution antimicrobial tests for bacteria that grow aerobically; M7-A5. National Committee for Clinical Laboratory Standards, Wayne PA 52000.
15. Société Française de Microbiologie, Institut Pasteur: Comité de L' Antibiogramme De La Societé Française de Microbiologie Communiqué 2000-2001 (edition Janvier 2001). Société Française de Microbiologie, Institut Pasteur, 28, rue du Dr Roux, F 75724 Paris Cedex 15, France 2001.
16. National Committee for Clinical Laboratory Standards: Performance standards for antimicrobial susceptibility testing; Eleventh Informational Supplement, M100-S11. National Committee for Clinical Laboratory Standards, Wayne PA, USA 2001.
17. Hadziyannis E, Tuohy M, Thomas L, Procop GW, Washington JA, Hal GS: Screening and confirmatory testing for extended spectrum β-lactamases (ESBL) in E. coli, Klebsiella pneumoniae and Klebsiella oxytoca clinical isolates. Diagn Microbiol Infect Dis 2000, 36:113-117.
18. Frank UK, Daschner FD, Leibovici L: Antimicrobial susceptibility patterns of bacteremic isolates from university hospitals in Denmark, Germany, Italy and Israel. Presented at the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA 2002. Abstract C2-301
19. Fridkin SK: Increasing prevalence of antimicrobial resistance in intensive care units. Crit Care Med 2001, 29:64-68.
20. Jones ME, Blosser-Middleton RS, Critchley IA, Thornsberry C, Karlowsky JA, Sahm DF: The activity of levofloxacin and comparator agents against clinical isolates of Streptococcus pneumoniae during 1999-2000. Chemotherapy 2002, 48:232-237.
21. Neuberger MM, Weinstein RA, Rydman R, Danzinger LH, Quinn JP: Antibiotic resistance among Gram-negative bacilli in US intensive care units. Implications for fluoroquinolone use. J Amer Medical Assoc 2003, 289:885-888.
22. Jones ME, Draghi DC, Master RN, Thornsberry C, Karlowsky JA, Critchley IA, Sahm DF: Trends in resistance among Enterobacteriaceae (isolated from in-patients and intensive-care unit patients in the US from 1998 to 2001. Presented at the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA 2002. Abstract C2-311
23. Friedland I, Stinson L, Ikaiddi M, Harm S, Woods G: Resistance in Enterobacteriaceae: results of a multicenter US ICU surveillance study (ISS), 1995-2000. Presented at the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA 2002. Abstract C2-313
24. Guidelines for the Management of Adults with Community-acquired Pneumonia. Am J Respir Crit Care Med 2001, 163:1730-1754.